FCX-013

N/A

Report date: 2023/10/26 16:41:12

Base Information

Drug NameFCX-013
Drug Alias NameHDF-LV-RTS-MMP1 + veledimex (linear scleroderma), Fibrocell Scienceautologous dermal fibroblasts expressing MMP1 (RheoSwitch Therapeutic System, linear scleroderma), Fibrocell ScienceFCX-013HDF-LV-RTS-MMP1
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Fibroblast therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionMMP1 gene transference
TargetsMatrix metalloproteinase-1
Therapy Area/IndicationsScleroderma, SystemicScleroderma, Localized
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFibrocell Science IncCastle Creek Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCastle Creek Biosciences LLC
Active IndicationsN/A
Inactive IndicationsScleroderma, SystemicScleroderma, Localized

Other Information

ATC CodeN/A
Related LinksN/A